Getinge invites fund managers, analysts, and media to Year-End Report 2025 conference call

Getinge will release its Year‑End Report 2025 on 27 January 2026 at 08:00 CET and hold a conference call at 10:00 CET hosted by CEO Mattias Perjos and CFO Agneta Palmér for fund managers, analysts and media; registration, teleconference access and a webcast (with a recording available for three years) have been provided. Investor relations contact is David Kördel; the company employs approximately 12,000 people and sells products in 135 countries, with the event primarily serving as an investor‑relations update rather than revealing new operational figures in this notice.

Analysis

Market structure: The event is an idiosyncratic earnings/call for Getinge (GETI‑B.ST). Direct beneficiaries of a positive surprise are Getinge suppliers/industrial peers (Stryker SYK, Fresenius Medical Care FME.DE) via sentiment spillover; losers are short-term procurement-dependent smaller OEMs if Getinge signals price pressure. Expect a 24–72h volatility window around Jan 27 with share moves of ±5–15% plausible; limited broader demand/supply impact for commodities or sovereign bonds but SEK may move ±0.5–1% on a material surprise.

Risk assessment: Tail risks include a product recall or major hospital-contract loss causing >30% share drawdown and potential covenant stress on any near-term debt (monitor bond spread widening >200bp). Immediate risk is trading volatility (days); short-term (weeks) is investor reaction to guidance; long-term (quarters) depends on hospital CAPEX cycles and FX translation (USD/EUR exposure). Hidden dependency: public procurement cycles in key markets (Germany/US) can flip order books quickly; catalysts include Q&A commentary on backlog, margins, and M&A.

Trade implications: Event-driven trades should be size-limited and hedged. Preferred direct play is a modest directional or volatility position on GETI‑B.ST for Jan 27–Mar 27 window, with outright shares or option structures to cap downside. Relative trades: long Getinge vs short Fresenius Medical Care (FME.DE) to isolate company-specific execution; monitor IV and set entry/exit rules (see decisions).

Contrarian angles: Consensus will treat this as routine; the market may underprice upside from improved sterile reprocessing demand and service recurring revenue — if management raises recurring revenue guide by >100bp, downside is limited. Conversely, if management flags procurement delays of >10% of expected orders, downside could be overdone. Historical parallels: post-pandemic capex recovery plays in medical equipment saw 20–40% moves within 3 months; that should guide sizing and stop rules.

Key Decisions for Investors

• Establish a 2–3% NAV long position in Getinge (GETI‑B.ST) no later than 48 hours before the Jan 27 call if implied volatility for Jan/Feb options is <40% and consensus EPS/guidance beat probability (broker delta) >60%; set hard stop-loss at -8% and initial take-profit at +15% within 3 months.
• If IV >40% or you want asymmetric risk, buy a 1–1.5% NAV 3‑month long call spread (buy ATM, sell +15% OTM) on GETI‑B.ST to limit premium spent while keeping upside exposure; roll/close within 6 weeks post‑call if no directional move.
• Implement a pair trade: long GETI‑B.ST 2% NAV and short FME.DE 2% NAV to isolate company execution risk; unwind if spread narrows/widens >7% or after 90 days.
• Avoid unhedged positions if share price gaps >5% pre-call; instead buy 2–3% NAV of 30‑day ATM straddles only if implied vol is < realized vol (realized 30‑day > implied by >5ppt) — cap option premium at 1.5% NAV.
• Monitor three triggers in next 30–60 days and act: (1) management changes to recurring revenue guide ±100bps, (2) SEK moves >1.0% vs EUR/USD (hedge FX exposure), (3) bond spread for any Getinge debt widening >150bp (reduce equity exposure by 50%).